Cite

    Andrea Galassi et al.. “Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency.” Expert opinion on drug safety, vol. 20, no. 11, 2021, pp. 1333–1349. http://access.bl.uk/ark:/81055/vdc_100144745172.0x000022